pregabalin
Commercial- Indications
- Neuropathic pain
Company intelligence / Profile preview
CNX Therapeutics
London, England, United Kingdomcnx-therapeutics.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
CNX Therapeutics supplies a portfolio of specialty brands and hospital products across Europe, focusing on essential medicines for neurological and psychiatric conditions as well as broader hospital use. The company was formed in August 2021 following Inflexion’s acquisition of Sunovion Pharmaceuticals Europe Limited. It has pan-European licensing rights to a patent-protected medicine for schizophrenia.
CNX emphasizes ESG principles and recently became a Certified B Corporation.
The company has announced recent product launches such as Nitrofurantoin Modified Release in the Netherlands through partnerships.
No detailed clinical trial results are publicly available; the business model centers on supply, licensing, and commercialization rather than novel drug discovery.
- Therapeutic areas
- OtherPsychiatryNeurology
- Modalities
- Small molecules (based on hospital and essential medicines focus)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Adalvo – partnership for Nitrofurantoin MR launch in the Netherlands
Beyond the preview
Go deeper on CNX Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNX Therapeutics.